Dynactin 1 Antikörper (AA 120-170)
Kurzübersicht für Dynactin 1 Antikörper (AA 120-170) (ABIN350280)
Target
Alle Dynactin 1 (DCTN1) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 120-170
-
Verwendungszweck
- Rabbit antibody to DCTN1 (120-170)
-
Spezifität
- Specific for DCTN1.
-
Kreuzreaktivität
- Human, Maus, Ratte
-
Kreuzreaktivität (Details)
- Other species not yet tested.
-
Aufreinigung
- IgG
-
Immunogen
- A synthetic peptide from AA 120-170 of human DCTN1 conjugated to an immunogenic carrier protein was used as the antigen. The peptide is homologous in rat and moue.
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- IHC WB. A concentration of 10-50,micro,g,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Reconstitute in 500 µl of sterile water. Centrifuge to remove any insoluble material.
-
Handhabung
- Avoid freeze and thaw cycles.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- Dynactin 1 (DCTN1)
-
Andere Bezeichnung
- DCTN1
-
Hintergrund
- FUNCTION: Required for the cytoplasmic dynein-driven retrograde movement of vesicles and organelles along microtubules. Dynein-dynactin interaction is a key component of the mechanism of axonal transport of vesicles and organelles. SUBUNIT: Large macromolecular complex of at least 10 components, p150(glued) binds directly to microtubules and to cytoplasmic dynein. Interacts with the C-terminus of MAPRE1 MAPRE2 and MAPRE3. SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm cytoskeleton. TISSUE SPECIFICITY: Brain. DISEASE: Defects in DCTN1 are the cause of progressive lower motor neuron disease. PLMND is a progressive dominant disease that has no sensory symptoms.
-
UniProt
- Q14203
-
Pathways
- M Phase, ER-Nucleus Signaling
Target
-